Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMolina Kesimpta Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    ModifiedMolina HealthcarePolicy C31192-A

    Kesimpta (ofatumumab), IL Medicaid Only

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C31192-A alerts

    Get alerted when Policy C31192-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Molina Healthcare IL Medicaid coverage and prior authorization requirements for Kesimpta (ofatumumab) in adults with relapsing forms of multiple sclerosis, including approval criteria, documentation, dosing, administration setting, and contraindications.

    Policy Summary
    PayerMolina Healthcare
    PolicyKesimpta (ofatumumab), IL Medicaid Only
    Policy CodePolicy C31192-A
    Change TypeModified
    Effective DateOct 1, 2026
    Next Review DateOct 1, 2027
    Key ActionDocument the 2024 McDonald diagnostic criteria, including applicable dissemination, central vein sign, paramagnetic rim lesion, or cerebrospinal fluid evidence, when submitting authorization.
    SourceLink
    POLICY UPDATE CHANGES

    The policy incorporates the 2024 revisions to the McDonald diagnostic criteria for multiple sclerosis.

    18+Minimum age
    12 monthsInitial authorization
    20 mgMaintenance dose
    Relapsing MSCovered indication

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Contraindication categories

    Coverage Criteria

    Initial Therapy

    Initial therapy is covered when ALL of the following are met.

    Initial therapy requirements

    • Age and diagnosis: Member is 18 years of age or older and has a documented relapsing form of multiple sclerosis, including relapsing-remitting multiple sclerosis (RRMS), secondary-progressive multiple sclerosis (SPMS) with relapses, or clinically isolated syndrome.Age >=18 years
    • Hepatitis B evaluation: Documentation of hepatitis B virus screening is required. For patients who are HBsAg-negative and HBcAb-positive or who are HBsAg-positive carriers, documentation of consultation with a liver disease expert is required before treatment.HBV screening; liver disease expert consultation when applicable
    • Highly active MS indicators: At least one indicator of a highly active course of multiple sclerosis is required.At least 1 of 6 indicators

      Indicators are MS onset age >40 years; male gender; African American; motor, sphincter, or brainstem-cerebellar symptoms; MRI lesions in the brainstem or spinal cord; or more than 2 acute relapses in the first 2 years of onset with significant sustained disability following relapse.

    • Contraindication review: The prescriber attests, or the clinical reviewer finds, that the member does not have any FDA-labeled contraindication that has not been addressed in the submitted documentation.No unaddressed contraindication

      Contraindications include active hepatitis B virus infection and a history of hypersensitivity to ofatumumab or a life-threatening injection-related reaction to Kesimpta.

    Continuation Therapy

    Continuation therapy is covered when ALL of the following are met.

    Continuation therapy requirements

    • Clinical response or stable disease: At least one of the following is documented: stable or decreased acute attacks within the last 6 months; lack of progression or sustained disability; or MRI within the last 6 months showing no development of new asymptomatic lesions.At least 1 of 3 outcomes
    • Safety during therapy: There is no evidence of intolerable adverse effects or drug toxicity, including serious opportunistic or recurrent infections.No intolerable adverse effects or toxicity

    Multiple Sclerosis Diagnostic Criteria

    The appendix describes the 2024 McDonald diagnostic algorithm for relapsing and progressive presentations of multiple sclerosis.

    Multiple sclerosis diagnostic framework

    • Dissemination in space: One or more hyperintense T2 lesions characteristic of multiple sclerosis are present in at least 2 of 5 typical central nervous system topographies, or there is an additional clinical attack implicating a different central nervous system site.At least 2 of 5 topographies

      Topographies are optic nerve, periventricular, cortical/juxtacortical, infratentorial, and spinal cord.

    • Additional diagnostic evidence: At least one applicable finding is present: a new hyperintense T2 or gadolinium-enhancing lesion on follow-up MRI; an additional clinical attack characteristic of multiple sclerosis; qualifying central vein sign positivity; paramagnetic rim lesion positivity; or cerebrospinal fluid positivity.Adults: 6 or more MRI lesions with a central vein sign; children younger than 18: 50% or more of MRI lesions with a central vein sign; paramagnetic rim lesion positivity: 1 or more lesion; cerebrospinal fluid positivity: restricted oligoclonal bands or kappa free-light chains

    Compendial approved off-label uses: None are identified. The policy does not provide coverage for off-label use.

    Kesimpta is contraindicated for members with active hepatitis B virus infection, a history of hypersensitivity to ofatumumab, or a life-threatening injection-related reaction to Kesimpta, unless the contraindication has been addressed in the submitted documentation.

    All other Kesimpta uses are considered experimental or investigational and are subject to Molina’s Off-Label policy.

    Coverage is excluded for Kesimpta in the presence of active hepatitis B virus infection, a history of hypersensitivity to ofatumumab, or a life-threatening injection-related reaction to Kesimpta.

    Concurrent treatment with another disease-modifying agent, B-cell-targeted therapy such as rituximab, belimumab, or ofatumumab, or a lymphocyte-trafficking blocker such as alemtuzumab or mitoxantrone is excluded.

    Coding and Eligibility Parameters

    HCPCSHCPCS
    N/ADESCRIPTION
    Minimum age
    Minimum age18 years of age and older
    Applies toKesimpta coverage for relapsing forms of multiple sclerosis
    Age requirementThe member must meet the policy's adult age restriction before therapy is authorized
    Highly active MS course
    Required thresholdAt least 1 of 6 indicators
    Clinical indicatorsMS onset age greater than 40 years; male gender; African American; or motor, sphincter, or brainstem-cerebellar symptoms
    MRI or relapse indicators

    Provider Actions and Authorization Requirements

    Prior Authorization

    Initial Authorization Requirements

    Before initial authorization, document that the member is 18 years of age or older and has a qualifying relapsing form of multiple sclerosis. Supporting documentation must include the required hepatitis B screening, highly active disease indicators, and confirmation that FDA-labeled contraindications have been addressed or are absent.

    • Qualifying diagnoses include relapsing-remitting MS (RRMS), secondary-progressive MS (SPMS) with relapses, or clinically isolated syndrome.
    • Document at least one highly active disease indicator: MS onset after age 40; male gender; African American race; motor, sphincter, or brainstem-cerebellar symptoms; MRI lesions in the brainstem or spinal cord; or more than two acute relapses in the first two years with significant sustained disability.
    • Document hepatitis B screening and, when HBsAg-negative/HBcAb-positive or HBsAg-positive, consultation with a liver disease expert before treatment.
    Prior Authorization

    Continuation Authorization Requirements

    For continuation authorization, document a positive clinical response or stable disease and the absence of intolerable adverse effects or drug toxicity.

    Policy Background

    Kesimpta (ofatumumab) is a monoclonal antibody used for relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary-progressive multiple sclerosis. This policy addresses Molina Healthcare Illinois Medicaid coverage and prior authorization requirements, including disease activity, hepatitis B evaluation, safety review, contraindications, and continuation of therapy.

    Clinical Definitions

    Relapsing forms of multiple sclerosis
    Relapsing-remitting MSRelapsing-remitting multiple sclerosis (RRMS)
    Secondary-progressive MSSecondary-progressive multiple sclerosis (SPMS) with relapses
    Clinically isolated syndromeClinically isolated syndrome
    Dissemination in space
    DefinitionDissemination in space is demonstrated by MS-characteristic T2 lesions in at least 2 of 5 typical central nervous system locations
    Alternative evidenceAn additional clinical attack involving a different central nervous system site may also demonstrate dissemination in space

    Initial Therapy

    Initial Therapy

    Initial therapy requires ALL of the following.

    Initial therapy

    • Diagnosis and age: Documented RRMS, SPMS with relapses, or clinically isolated syndrome in a member 18 years of age or older.Age >=18 years
    • HBV screening and consultation: Hepatitis B virus screening is documented. A liver disease expert consultation is documented before treatment for HBsAg-negative and HBcAb-positive patients or HBsAg-positive HBV carriers.HBV screening; consultation when applicable
    • Highly active disease: At least one listed indicator of a highly active course of multiple sclerosis is present.

    Continuation Therapy

    Continuation Therapy

    Continuation therapy requires ALL of the following.

    Continuation therapy

    • Response or stable disease: At least one of the following is documented: stable or decreased acute attacks within the last 6 months; lack of progression or sustained disability; or MRI within the last 6 months showing no new asymptomatic lesions.At least 1 of 3 outcomes
    • Tolerability: No intolerable adverse effects or drug toxicity, including serious opportunistic or recurrent infections.No intolerable toxicity

    Dose and Quantity Limits

    Kesimpta (ofatumumab) dosing schedule
    Initial dosing20 mg by subcutaneous injection at Weeks 0, 1, and 2
    Maintenance dose20 mg by subcutaneous injection once monthly
    Maintenance startBegin monthly dosing at Week 4

    Administration Setting

    Billing Rule

    Use home self-administration

    Injectable medication is recommended for pharmacy benefit coverage and patient self-administration at home.

    Policy Summary
    PayerMolina Healthcare
    PolicyKesimpta (ofatumumab), IL Medicaid Only
    Policy CodePolicy C31192-A
    Change TypeModified
    Effective DateOct 1, 2026
    Next Review DateOct 1, 2027
    Key ActionDocument the 2024 McDonald diagnostic criteria, including applicable dissemination, central vein sign, paramagnetic rim lesion, or cerebrospinal fluid evidence, when submitting authorization.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Eligibility ParametersProvider Actions and Authorization RequirementsPolicy BackgroundClinical DefinitionsInitial TherapyContinuation TherapyDose and Quantity LimitsAdministration Setting

    The specific evidence required depends on the clinical presentation and applicable McDonald criteria pathway.

    MRI lesions in the brainstem or spinal cord; or more than 2 acute relapses in the first 2 years of onset with significant sustained disability following relapse
    Continuation clinical response or stability
    Required thresholdAt least 1 of 3 outcomes
    Relapse controlStable or decreased acute attacks within the last 6 months
    Disease stabilityLack of progression or sustained disability
    MRI stabilityMRI within the last 6 months showing no new asymptomatic lesions
    Central vein sign positivity
    Adult criterion6 or more MRI lesions with a central vein sign (CVS)
    Pediatric criterionFor children younger than 18, 50% or more of MRI lesions have a CVS
    Imaging basisCVS positivity is assessed on MRI lesions showing a central vein sign
    Adult central vein sign MRI criterion
    PopulationAdults
    MRI threshold6 or more MRI lesions have a central vein sign (CVS)
    Diagnostic useThe adult criterion is one qualifying pathway in the multiple sclerosis diagnostic algorithm
    Pediatric central vein sign MRI criterion
    PopulationChildren younger than 18
    MRI threshold50% or more of MRI lesions have a central vein sign (CVS)
    Diagnostic useThe pediatric criterion is one qualifying pathway in the multiple sclerosis diagnostic algorithm
    Live or live-attenuated vaccine timing
    Vaccine typeLive or live-attenuated vaccines
    TimingAdminister at least 4 weeks prior to Kesimpta initiation
    During treatmentLive-attenuated or live vaccines are not recommended during treatment and after discontinuation until B-cell repletion
    Non-live vaccine timing
    Vaccine typeNon-live vaccines
    TimingAdminister whenever possible at least 2 weeks prior to Kesimpta initiation
    GuidanceImmunizations should be administered according to immunization guidelines
    • Within the last 6 months, document stable or decreased acute attacks (relapses), lack of progression or sustained disability, or MRI showing no new asymptomatic lesions.
    • Document no intolerable adverse effects or drug toxicity, including serious opportunistic or recurrent infections.
    Prior Authorization

    Kesimpta Prior Authorization Requirements

    Kesimpta prior authorization requires documentation of the covered indication, contraindication review, required baseline testing and immunization timing, and review of concurrent therapies before treatment begins.

    • Confirm relapsing MS and applicable initial or continuation criteria.
    • Review for active hepatitis B infection, hypersensitivity to ofatumumab, or a life-threatening injection-related reaction.
    • Obtain quantitative serum immunoglobulins before initiation; consult immunology experts when levels are low and monitor levels during treatment as clinically appropriate.
    • Administer immunizations at least 4 weeks before initiation for live or live-attenuated vaccines and, whenever possible, at least 2 weeks before initiation for non-live vaccines.
    • Confirm the member is not receiving another disease-modifying agent, B-cell-targeted therapy, or lymphocyte-trafficking blocker.
    Documentation Required

    General Documentation Required

    Molina may require additional documentation for coverage determination, quality improvement, and fraud, waste, and abuse prevention. Providers should be prepared to submit records supporting medical necessity and benefit eligibility.

    • Requested documentation may include patient records, test results, and credentials of the provider ordering or performing the drug or service.
    Documentation Required

    Multiple Sclerosis Diagnosis

    Document the member’s diagnosis of multiple sclerosis (MS) in the clinical record submitted for review.

    Documentation Required

    Initial Therapy Clinical Documentation

    For initial therapy, document the specific relapsing MS subtype, hepatitis B screening, and any required specialist consultation before starting Kesimpta.

    • Include RRMS, SPMS with relapses, or clinically isolated syndrome when applicable.
    • For HBsAg-negative/HBcAb-positive patients or HBV carriers who are HBsAg-positive, document consultation with a liver disease expert before treatment.
    • Document the highly active MS indicators supporting the request.
    Documentation Required

    Continuation Therapy Documentation

    For continuation therapy, document clinical response or stable disease and confirm that treatment has not caused intolerable adverse effects or drug toxicity.

    • Use relapse history, disability progression, or MRI findings from the last 6 months to support response or stability.
    • Address serious opportunistic or recurrent infections and other clinically significant toxicity.
    Note

    Updated FDA Labeling

    If Kesimpta receives an updated FDA label within the preceding 180 days, Molina will review medical necessity using the updated FDA labeling information. Coverage may be determined case by case until Molina updates the criteria through clinical governance.

    • Additional information may be requested to allow adequate review.
    Documentation Required

    Baseline Immunoglobulin Evaluation

    Before initiating Kesimpta, obtain quantitative serum immunoglobulin testing and address low levels with appropriate specialist input.

    • Consult an immunology expert before initiation when serum immunoglobulins are low.
    • Monitor quantitative serum immunoglobulins during treatment, especially with opportunistic or recurrent infections, and after discontinuation until B-cell repletion.
    Documentation Required

    Pre-Treatment Immunization Timing

    Document that required immunizations were administered before treatment according to applicable immunization guidance.

    • Give live or live-attenuated vaccines at least 4 weeks before Kesimpta initiation.
    • Whenever possible, give non-live vaccines at least 2 weeks before initiation.
    • Live or live-attenuated vaccines are not recommended during treatment or after discontinuation until B-cell repletion.
    Prior Authorization

    Concurrent Therapy Review

    Review and document concurrent therapy status before authorization. The member must not be receiving prohibited overlapping therapies with Kesimpta.

    • Confirm absence of another disease-modifying agent (DMA) other than the requested agent.
    • Confirm absence of B-cell-targeted therapy, such as rituximab, belimumab, or ofatumumab.
    • Confirm absence of a lymphocyte-trafficking blocker, such as alemtuzumab or mitoxantrone.
    Denial Risk

    Unaddressed Contraindication

    Coverage may be denied when an FDA-labeled contraindication is present and has not been addressed by the prescriber in the submitted documentation.

    • Contraindications include active hepatitis B virus infection, a history of hypersensitivity to ofatumumab, or a life-threatening injection-related reaction to Kesimpta.
    Denial Risk

    Insufficient Supporting Documentation

    Molina may deny reimbursement or take other appropriate action when submitted documentation does not support medical necessity, non-investigational use, benefit eligibility, or compliance with policy requirements.

    • Molina may also act when documentation demonstrates inappropriate or excessive billing or other practices.
    Denial Risk

    Initial Criteria Not Met

    Initial criteria are not met unless the request documents a qualifying relapsing form of MS, required hepatitis B screening and consultations, and the clinical factors supporting a highly active course of disease.

    • Document RRMS, SPMS with relapses, or clinically isolated syndrome.
    • Complete hepatitis B screening; obtain liver disease expert consultation when HBsAg-negative/HBcAb-positive or HBsAg-positive.
    • Document at least one qualifying highly active disease indicator and address FDA-labeled contraindications.
    Denial Risk

    Experimental or Investigational Use

    All other uses of Kesimpta are considered experimental or investigational and follow Molina’s Off-Label policy.

    Denial Risk

    Contraindications

    Kesimpta is contraindicated for active hepatitis B virus infection, a history of hypersensitivity to ofatumumab, or a life-threatening injection-related reaction to Kesimpta.

    • Do not initiate or continue treatment when a listed contraindication is present unless it has been appropriately addressed and documented as required.
    Denial Risk

    Prohibited Concurrent Therapy

    Coverage may be denied when the member is receiving prohibited concurrent therapy with Kesimpta.

    • Do not use with another disease-modifying agent other than the requested agent.
    • Do not use with B-cell-targeted therapy, including rituximab, belimumab, or ofatumumab.
    • Do not use with a lymphocyte-trafficking blocker, including alemtuzumab or mitoxantrone.
    CNS locations
    Optic nerve; periventricular; cortical or juxtacortical; infratentorial; and spinal cord
    Appendix abbreviations
    CVSCentral vein sign
    PRLParamagnetic rim lesion
    CSFCerebrospinal fluid
    DITDissemination in time
    Dissemination in space (DIS)
    MRI findingOne or more hyperintense T2 lesions characteristic of multiple sclerosis
    Required distributionLesions must occur in at least 2 of 5 MS-typical topographies
    TopographiesOptic nerve; periventricular; cortical or juxtacortical; infratentorial; and spinal cord
    Clinical alternativeAn additional clinical attack implicating a different central nervous system site
    Dissemination in time (DIT)
    Follow-up MRI evidenceA new hyperintense T2 lesion or one or more gadolinium-enhancing lesions on follow-up MRI
    Clinical evidenceAn additional clinical attack characteristic of multiple sclerosis
    MeaningThese findings demonstrate dissemination in time
    Central vein sign (CVS)
    MRI appearanceA thin linear hypointense line or dot representing a small venule
    Lesion locationThe venule is positioned centrally within a demyelinating multiple sclerosis white matter lesion
    Imaging sequenceThe sign is identified on susceptibility-weighted MRI
    Paramagnetic rim lesion (PRL)
    MRI appearanceA lesion with a hyperintense core on T2-weighted MRI surrounded by a hypointense rim on susceptibility-weighted MRI
    Positivity thresholdOne or more paramagnetic rim lesions on MRI
    AbbreviationPRL means paramagnetic rim lesion
    Cerebrospinal fluid (CSF) positivity
    DefinitionCerebrospinal fluid positivity
    Qualifying finding 1Restricted oligoclonal bands
    Qualifying finding 2Kappa free-light chains
    Progressive multifocal leukoencephalopathy (PML)
    DefinitionProgressive multifocal leukoencephalopathy (PML) is an opportunistic viral infection of the brain caused by JC virus (JCV)
    Risk contextPML typically occurs in patients who are immunocompromised
    Potential outcomePML usually leads to death or severe disability
    Required actionWithhold Kesimpta at the first sign or symptom suggestive of PML and perform an appropriate diagnostic evaluation; discontinue treatment if PML is confirmed
    At least 1 of 6 indicators

    Indicators are MS onset age >40 years; male gender; African American; motor, sphincter, or brainstem-cerebellar symptoms; MRI lesions in the brainstem or spinal cord; or more than 2 acute relapses in the first 2 years of onset with significant sustained disability following relapse.

  1. Contraindication attestation: The prescriber or clinical reviewer confirms that there are no unaddressed FDA-labeled contraindications.No unaddressed contraindication
  2. Initial Safety and Concurrent-Therapy Requirements

    Before initiating Kesimpta, the following safety and concurrent-therapy requirements apply.

    Initial Kesimpta safety requirements

    • Baseline immunoglobulin evaluation: Perform quantitative serum immunoglobulin testing before initiation; consult an immunology expert before initiation when serum immunoglobulins are low.Testing before initiation
    • Vaccination timing: Administer immunizations according to immunization guidelines before treatment when possible.Live or live-attenuated vaccines: at least 4 weeks before initiation; non-live vaccines: whenever possible, at least 2 weeks before initiation

      Live vaccines are not recommended during treatment and after discontinuation until B-cell repletion.

    • No prohibited concurrent therapy: The member is not currently receiving another disease-modifying agent, B-cell-targeted therapy, or lymphocyte-trafficking blocker.

      Examples include rituximab, belimumab, ofatumumab, alemtuzumab, and mitoxantrone.